GT BIOPHARMA, INC.

Profile

Company Names

GT BIOPHARMA, INC.
OXIS INTERNATIONAL INC

Addresses

505 MONTGOMERY STREET, 10TH FLOOR, SAN FRANCISCO, CA 94111

9350 WILSHIRE BLVD., SUITE 203, BEVERLY HILLS, CA 90212

9350 WILSHIRE BLVD, SUITE 203, BEVERLY HILLS, CA 90212

100 SOUTH ASHLEY DRIVE, STE 600, TAMPA, FL 33602

1825 K STREET, SUITE 510, WASHINGTON, DC 20006

1825 K STREET, SUITE 510, WASHINGTON, DC 20006

4830 W KENNEDY BLVD, SUITE 600, TAMPA, FL 33609

4830 WEST KENNEDY BLVD, SUITE 600, TAMPA, FL 33626

468 N. CAMDEN DR., 2ND FLOOR, BEVERLY HILLS, CA 90210

Phone Numbers

(800) 304-9888
800-304-9888
(310) 860-5184

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY, OTHER HEALTH CARE

Year Incorporated:

> 5 years ago

State Incorporated:

DELAWARE

Total Amount Raised:

$33,547,358.00

Number of Funding Rounds:

10
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
10
2025-05-14 
$0.00 
$20,000,000.00 
$20,000,000.00 
Equity 
9
2025-05-12 
$5,950,000.00 
$5,950,000.00 
$0.00 
Equity 
8
2025-02-25 
$1,280,358.00 
$1,280,358.00 
$0.00 
Equity 
7
2020-04-20 
$5,607,000.00 
INDEFINITE 
INDEFINITE 
Debt 
6
2018-08-02 
$5,140,000.00 
$5,140,000.00 
$0.00 
Equity 
5
2018-01-23 
$7,055,000.00 
$7,055,000.00 
$0.00 
Debt 
4
2016-08-31 
$4,540,000.00 
$4,540,000.00 
$0.00 
Equity, Debt 
3
2015-07-09 
$500,000.00 
$1,500,000.00 
$1,000,000.00 
Equity, Debt 
2
2015-02-20 
$2,050,000.00 
$3,000,000.00 
$950,000.00 
Equity, Debt 
1
2014-07-24 
$1,425,000.00 
$1,425,000.00 
$0.00 
Debt 
People
First Name
Middle Name
Last Name
Titles
Related Companies
JON 
 
BONFIGLIO 
DIRECTOR
GT BIOPHARMA, INC.
MICHAEL 
 
BREEN 
EXECUTIVE OFFICER, DIRECTOR
GROWING ENERGY LABS, INC.   |  WIZARD ENTERTAINMENT, INC.   |  WIZARD BRANDS, INC.   |  ONWARD INVESTORS VALUE FUND III, L.P.   |  GT BIOPHARMA, INC.
CHARLES 
 
CASAMENTO 
DIRECTOR
INTERNATIONAL STEM CELL CORP   |  AZURRX BIOPHARMA, INC.   |  ETON PHARMACEUTICALS, INC.   |  RELMADA THERAPEUTICS, INC.   |  FIRST WAVE BIOPHARMA, INC.   |  GT BIOPHARMA, INC.
ANTHONY 
 
CATALDO 
DIRECTOR, EXECUTIVE OFFICER
GENESIS BIOPHARMA, INC   |  OXIS INTERNATIONAL INC   |  GT BIOPHARMA, INC.
ANTHONY 
J. 
CATALDO 
DIRECTOR
GT BIOPHARMA, INC.
KATHLEEN 
 
CLARENCE-SMITH 
EXECUTIVE OFFICER, DIRECTOR
CHASE PHARMACEUTICALS CORP   |  GT BIOPHARMA, INC.   |  CHASE THERAPEUTICS CORP
GEOFFREY 
B. 
DAVIS 
DIRECTOR
GT BIOPHARMA, INC.
ANSHUMAN 
 
DUBE 
DIRECTOR
OXIS INTERNATIONAL INC   |  VIVA-SX LLC - SERIES B   |  SPX OPPORTUNITY SERIES I, A SERIES OF SPX OPPORTUNITY FUND, LLC   |  SPX OPPORTUNITY SERIES II, A SERIES OF SPX OPPORTUNITY FUND, LLC   |  VIVA PRIVATE INVESTMENTS LLC - SERIES B   |  VIVA-SX LLC - SERIES F   |  VIVA-SX LLC - SERIES F-1   |  VIVA PRIVATE INVESTMENTS LLC - SERIES F   |  VIVA PRIVATE INVESTMENTS LLC - SERIES G
KENNETH 
 
EATON 
EXECUTIVE OFFICER, DIRECTOR
OXIS INTERNATIONAL INC
PETER 
 
KIENER 
DIRECTOR
ZYNGENIA, INC.   |  RESOLVE THERAPEUTICS LLC   |  CUE BIOPHARMA, INC.   |  TETRAGENETICS INC   |  GT BIOPHARMA, INC.   |  WUGEN, INC.
HILARY 
 
KRAMER 
DIRECTOR
GT BIOPHARMA, INC.
ANDREW 
 
RITTER 
DIRECTOR
RITTER PHARMACEUTICALS INC   |  MYOSIN THERAPEUTICS INC.   |  GT BIOPHARMA, INC.
DAVID 
 
SALOFF 
DIRECTOR
IVIVI TECHNOLOGIES, INC.   |  OXIS INTERNATIONAL INC   |  TRANSPARENT HEALTH MARKETPLACE, LLC
RAJESH 
 
SHROTRIYA 
DIRECTOR
GT BIOPHARMA, INC.
ALAN 
 
URBAN 
EXECUTIVE OFFICER
RESEARCH SOLUTIONS, INC.   |  GT BIOPHARMA, INC.
RAYMOND 
 
URBANSKI 
EXECUTIVE OFFICER
GT BIOPHARMA, INC.
STEVEN 
 
WELDON 
EXECUTIVE OFFICER, DIRECTOR
GROWBLOX SCIENCES, INC.   |  SIGNATURE EXPLORATION + PRODUCTION CORP.   |  OXIS INTERNATIONAL INC   |  GT BIOPHARMA, INC.
BRUCE 
 
WENDEL 
DIRECTOR
VERASTEM, INC.   |  GT BIOPHARMA, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2025-05-28
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2025-05-14 
2025-05-27
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2025-05-12 
2025-03-07
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2025-02-25 
2020-07-23
D/A
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2020-04-20 
2020-06-12
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2020-04-20 
2018-08-17
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2018-08-02 
2018-02-06
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
$1 - $1,000,000 
Debt 
2018-01-23 
2017-09-14
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
$1 - $1,000,000 
Equity, Debt 
2016-08-31 
2015-07-27
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
$1 - $1,000,000 
Equity, Debt 
2015-07-09 
2015-03-16
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
$1 - $1,000,000 
Equity, Debt 
2015-02-20 
2014-07-31
D
Link
OTHER HEALTH CARE 
PHARMACEUTICAL PREPARATIONS [2834] 
$1 - $1,000,000 
Debt 
2014-07-24 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
H.C. WAINWRIGHT + CO., LLC
375